Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

36.52 -0.20 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported weak first quarter 2025 results which featured drastically lowered full-year... 
Via StockStory
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates. 
Via Benzinga
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment. 
Via Investor's Business Daily
Topics Death
Exposures Death Product Safety
Earnings Scheduled For May 6, 2025
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
Via Benzinga
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sarepta Shares Slide To 2017 Lows On Revenue Cut, But Retail Bulls Remain Defiant
Despite strong Q1 sales led by Elevidys, Sarepta raised spending forecasts and lowered full-year guidance, triggering a sharp market reaction. 
Via Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per... 
Via StockStory
Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why
Sarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Tuesday?
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions. 
Via MarketBeat
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise. 
Via Stocktwits
Topics Government
Exposures Political
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook. 
Via Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
The holds are temporary while the teenager's death is under investigation. 
Via Investor's Business Daily
Topics Death
Exposures Death
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.